MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 596337 | Name: Ubidecarenone
Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Ubidecarenone (Coenzyme Q10, CoQ10) is a vital component of the mitochondrial electron transport chain, where it facilitates ATP production and serves as a powerful antioxidant. It primarily targets mitochondrial complex I and III, playing a crucial role in cellular energy metabolism and protecting against oxidative stress. Clinically, CoQ10 is used for treating cardiovascular diseases like heart failure and hypertension, as well as mitochondrial and neurodegenerative disorders such as Parkinson’s.

Chemical Structure

Ubidecarenone
Ubidecarenone
CAS#303-98-0

Theoretical Analysis

MedKoo Cat#: 596337

Name: Ubidecarenone

CAS#: 303-98-0

Chemical Formula: C59H90O4

Exact Mass: 862.6839

Molecular Weight: 863.36

Elemental Analysis: C, 82.08; H, 10.51; O, 7.41

Price and Availability

Size Price Availability Quantity
500mg USD 200.00
1g USD 350.00
2g USD 600.00
5g USD 850.00
Bulk Inquiry
Buy Now
Add to Cart
Related CAS #
No Data
Synonym
Ubidecarenone; COQ10; Vitamin Q; Coenzyme Q10; ubiquinone; coenzyme Q; Q 199; NSC 140665; NSC -40665; NSC140665;
IUPAC/Chemical Name
2-((2E,6E,10E,14E,18E,22E,26E,30E,34E)-3,7,11,15,19,23,27,31,35,39-decamethyltetraconta-2,6,10,14,18,22,26,30,34,38-decaen-1-yl)-5,6-dimethoxy-3-methylcyclohexa-2,5-diene-1,4-dione
InChi Key
ACTIUHUUMQJHFO-UPTCCGCDSA-N
InChi Code
InChI=1S/C59H90O4/c1-44(2)24-15-25-45(3)26-16-27-46(4)28-17-29-47(5)30-18-31-48(6)32-19-33-49(7)34-20-35-50(8)36-21-37-51(9)38-22-39-52(10)40-23-41-53(11)42-43-55-54(12)56(60)58(62-13)59(63-14)57(55)61/h24,26,28,30,32,34,36,38,40,42H,15-23,25,27,29,31,33,35,37,39,41,43H2,1-14H3/b45-26+,46-28+,47-30+,48-32+,49-34+,50-36+,51-38+,52-40+,53-42+
SMILES Code
O=C(C(OC)=C1OC)C(C)=C(C/C=C(C)/CC/C=C(C)/CC/C=C(C)/CC/C=C(C)/CC/C=C(C)/CC/C=C(C)/CC/C=C(C)/CC/C=C(C)/CC/C=C(C)/CC/C=C(C)\C)C1=O
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 863.36 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Seo JS. Chronological change of left ventricular global longitudinal strain in patients with maternally inherited diabetes and deafness: A case series. Medicine (Baltimore). 2024 Mar 8;103(10):e37447. doi: 10.1097/MD.0000000000037447. PMID: 38457558; PMCID: PMC10919458. 2: Scarcella S, Dell'Arti L, Gagliardi D, Magri F, Govoni A, Velardo D, Mainetti C, Minorini V, Ronchi D, Piga D, Comi GP, Corti S, Meneri M. Ischemic optic neuropathy as first presentation in patient with m.3243 A > G MELAS classic mutation. BMC Neurol. 2023 Apr 24;23(1):165. doi: 10.1186/s12883-023-03198-3. PMID: 37095452; PMCID: PMC10123965. 3: Starace M, Carpanese MA, Alessandrini A, Bruni F, Piraccini BM. Oral supplementation in female telogen effluvium: a clinical and instrumental objective evidence of efficacy and tolerability of new oral cosmetic treatment. Ital J Dermatol Venerol. 2023 Feb;158(1):55-59. doi: 10.23736/S2784-8671.22.07416-3. Epub 2023 Jan 16. PMID: 36645365. 4: Kadry MO, Abdel Megeed RM. Ubiquitous toxicity of Mercuric Chloride in target tissues and organs: Impact of Ubidecarenone and liposomal-Ubidecarenone STAT 5A/ PTEN /PI3K/AKT signaling pathways. J Trace Elem Med Biol. 2022 Dec;74:127058. doi: 10.1016/j.jtemb.2022.127058. Epub 2022 Aug 5. PMID: 35952450. 5: Bejan CA, Cahill KN, Staso PJ, Choi L, Peterson JF, Phillips EJ. DrugWAS: Drug-wide Association Studies for COVID-19 Drug Repurposing. Clin Pharmacol Ther. 2021 Dec;110(6):1537-1546. doi: 10.1002/cpt.2376. Epub 2021 Aug 10. PMID: 34314511; PMCID: PMC8426999. 6: Hajiluian G, Heshmati J, Jafari Karegar S, Sepidarkish M, Shokri A, Shidfar F. Diabetes, Age, and Duration of Supplementation Subgroup Analysis for the Effect of Coenzyme Q10 on Oxidative Stress: A Systematic Review and Meta- Analysis. Complement Med Res. 2021;28(6):557-570. English. doi: 10.1159/000515249. Epub 2021 Apr 16. PMID: 33866314. 7: Dadali T, Diers AR, Kazerounian S, Muthuswamy SK, Awate P, Ng R, Mogre S, Spencer C, Krumova K, Rockwell HE, McDaniel J, Chen EY, Gao F, Diedrich KT, Vemulapalli V, Rodrigues LO, Akmaev VR, Thapa K, Hidalgo M, Bose A, Vishnudas VK, Moser AJ, Granger E, Kiebish MA, Gesta S, Narain NR, Sarangarajan R. Elevated levels of mitochondrial CoQ10 induce ROS-mediated apoptosis in pancreatic cancer. Sci Rep. 2021 Mar 11;11(1):5749. doi: 10.1038/s41598-021-84852-z. PMID: 33707480; PMCID: PMC7952582. 8: Sun J, Patel CB, Jang T, Merchant M, Chen C, Kazerounian S, Diers AR, Kiebish MA, Vishnudas VK, Gesta S, Sarangarajan R, Narain NR, Nagpal S, Recht L. High levels of ubidecarenone (oxidized CoQ10) delivered using a drug-lipid conjugate nanodispersion (BPM31510) differentially affect redox status and growth in malignant glioma versus non-tumor cells. Sci Rep. 2020 Aug 17;10(1):13899. doi: 10.1038/s41598-020-70969-0. PMID: 32807842; PMCID: PMC7431533. 9: Zhang L, Ashizawa T, Peng D. Primary coenzyme Q10 deficiency due to COQ8A gene mutations. Mol Genet Genomic Med. 2020 Oct;8(10):e1420. doi: 10.1002/mgg3.1420. Epub 2020 Aug 2. PMID: 32743982; PMCID: PMC7549598. 10: Wang J, Wang H, Xia Q. Ubidecarenone-Loaded Nanostructured Lipid Carrier (UB-NLC): Percutaneous Penetration and Protective Effects Against Hydrogen Peroxide-Induced Oxidative Stress on HaCaT Cells. Int J Mol Sci. 2018 Jun 25;19(7):1865. doi: 10.3390/ijms19071865. PMID: 29941831; PMCID: PMC6073307. 11: Muheem A, Shakeel F, Warsi MH, Jain GK, Ahmad FJ. A Combinatorial Statistical Design Approach to Optimize the Nanostructured Cubosomal Carrier System for Oral Delivery of Ubidecarenone for Management of Doxorubicin-Induced Cardiotoxicity: In Vitro-In Vivo Investigations. J Pharm Sci. 2017 Oct;106(10):3050-3065. doi: 10.1016/j.xphs.2017.05.026. Epub 2017 May 25. PMID: 28552692. 12: Roese E, Bunjes H. Drug release studies from lipid nanoparticles in physiological media by a new DSC method. J Control Release. 2017 Jun 28;256:92-100. doi: 10.1016/j.jconrel.2017.04.032. Epub 2017 Apr 24. PMID: 28450207. 13: Rosenblatt KM, Bunjes H. Evaluation of the drug loading capacity of different lipid nanoparticle dispersions by passive drug loading. Eur J Pharm Biopharm. 2017 Aug;117:49-59. doi: 10.1016/j.ejpb.2017.03.010. Epub 2017 Mar 16. PMID: 28315731. 14: Tort F, Ugarteburu O, Torres MA, García-Villoria J, Girós M, Ruiz A, Ribes A. Lysine Restriction and Pyridoxal Phosphate Administration in a NADK2 Patient. Pediatrics. 2016 Nov;138(5):e20154534. doi: 10.1542/peds.2015-4534. Epub 2016 Oct 18. PMID: 27940755. 15: Kalenikova EI, Tokareva OV, Kulyak OU, Gorodetskaya EA, Medvedev OS. [COMPARATIVE CARDIOPROTECTIVE EFFICACY OF COENZYME Q10 AND MEXICOR IN EXPERIMENTAL MODEL OF MYOCARDIAL INFARCTION IN RATS]. Eksp Klin Farmakol. 2015;78(6):12-4. Russian. PMID: 26292508. 16: Coenzyme Q10 and statin-related myopathy. Drug Ther Bull. 2015 May;53(5):54-6. doi: 10.1136/dtb.2015.5.0325. PMID: 25977402. 17: Zaki NM. Strategies for oral delivery and mitochondrial targeting of CoQ10. Drug Deliv. 2016 Jul;23(6):1868-81. doi: 10.3109/10717544.2014.993747. Epub 2014 Dec 29. PMID: 25544601. 18: Mignot C, Apartis E, Durr A, Marques Lourenço C, Charles P, Devos D, Moreau C, de Lonlay P, Drouot N, Burglen L, Kempf N, Nourisson E, Chantot-Bastaraud S, Lebre AS, Rio M, Chaix Y, Bieth E, Roze E, Bonnet I, Canaple S, Rastel C, Brice A, Rötig A, Desguerre I, Tranchant C, Koenig M, Anheim M. Phenotypic variability in ARCA2 and identification of a core ataxic phenotype with slow progression. Orphanet J Rare Dis. 2013 Oct 28;8:173. doi: 10.1186/1750-1172-8-173. PMID: 24164873; PMCID: PMC3843540. 19: Buompadre MC. Avances en el tratamiento de las ataxias crónicas [Therapeutic developments in chronic ataxias]. Medicina (B Aires). 2013;73 Suppl 1:49-54. Spanish. PMID: 24072051. 20: Nanjwade BK, Kadam VT, Manvi FV. Formulation and characterization of nanostructured lipid carrier of ubiquinone (Coenzyme Q10). J Biomed Nanotechnol. 2013 Mar;9(3):450-60. doi: 10.1166/jbn.2013.1560. PMID: 23621001.